Ophthalmology

Directors from the Moran Eye Center discussed researching gene therapy approaches targeting HTRA1 in AMD.

Review top news and interview highlights from the week ending September 24, 2021.

The recent FDA Advisory Committee meeting follows a turbulent year for gene therapy studies.

Brian Culley, chief executive officer, Lineage Cell Therapeutics, discussed updated data from the phase 1/2 study of OpRegen.

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the 8,000 donated eye repository that aided his research in AMD.

Lineage Cell Therapeutics announced promising data from interim results of the phase 1/2a clinical trial assessing the cell therapy.

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.

Researchers are exploring gene-independent therapeutic strategies to circumvent the challenges of gene-replacement therapies.

RGX-314 is being developed to target wet AMD, diabetic retinopathy, and other chronic retinal diseases.

A single-dose gene therapy for uveitis could fill an important treatment gap for patients.

Samarendra Mohanty, PhD, cofounder and president, Nanoscope Therapeutics, discussed the company’s technological platforms and RESTORE trial data.

Directors from the Moran Eye Center discussed their research on the genetics of age-related macular degeneration.

A new animal model will facilitate the study and development of gene therapies in retinal diseases.

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.

An international panel of experts discussed needs and challenges in the field.

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.

The research director at the Moran Eye Center discussed the genetics of developing age-related macular degeneration.

Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Targeted CRISPR therapy has potential in treating inherited retinal diseases.

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the research his team has been conducting in AMD.

Parexel cell and gene therapy director Izaskun Elorza, MD, shares key factors for industry to consider as this emerging field becomes more prominent.

Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.

Clinical trials for both AGTC-401 and AGTC-402 show promising results.